Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Airbus Joins Air India A320 Altitude Drop Probe 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Emasan AG, the investment arm of the Sandoz family, has sold a significant stake in Swiss pharmaceutical giant Novartis (SIX:NOVN), generating 2.6 billion Swiss francs ($2.90 billion).
The sale, conducted through an accelerated bookbuilding process, saw Emasan AG offload 26.5 million Novartis shares at 98.25 Swiss francs each. Goldman Sachs, acting as the bookrunner, confirmed the transaction on Wednesday.
This move marks a substantial capital realization for Emasan AG, highlighting a strategic shift in the investment portfolio of the Sandoz family. Novartis, a global leader in pharmaceuticals, has been a key holding for Emasan AG, making this divestment particularly notable for investors tracking the Swiss stock market.
The deal is expected to impact Novartis’s share performance, given the scale of the transaction. Market analysts are closely watching how this sell-off influences investor sentiment and Novartis’s future stock valuation.
This article was generated with AI assistance and reviewed by an editor.
